- Source: MMAI
5-Methoxy-6-methyl-2-aminoindane (MMAI) is a drug of the 2-aminoindane group developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a less neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogenic effects in humans. It has been sold as a designer drug and research chemical online since 2010.
MMAI has been shown to relieve stress-induced depression in rats more robustly than sertraline, and as a result it has been suggested that SSRAs like MMAI and 4-methylthioamphetamine (4-MTA) could be developed as novel antidepressants with a faster onset of therapeutic action and superior effectiveness to current antidepressants such as the selective serotonin reuptake inhibitors (SSRIs).
MMAI alone does not appear to produce serotonergic neurotoxicity with either acute or chronic administration in animals. However, subsequent research found that a single high dose of MMAI could produce significant serotonergic neurotoxicity. In addition, combination of MMAI with the dopamine releasing agent dextroamphetamine has been found to produce dose-dependent serotonergic neurotoxicity in animals. Hence, MMAI is not a fully non-neurotoxic MDMA analogue.
References
Kata Kunci Pencarian:
- Kitab Daniel
- Darius orang Media
- MMAI
- Methamphetamine
- Borax combo
- Smith School of Business
- Glicko rating system
- MDMA
- C11H15NO
- Adderall
- Serotonin
- Pseudoephedrine
